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Abstract
Background: Insulin gene (INS) mutations have recently been described as a common cause of permanent
neonatal diabetes (PNDM) and a rare cause of diabetes diagnosed in childhood or adulthood.
Methods: INS was sequenced in 116 maturity-onset diabetes of the young (MODYX) patients (n = 48 Danish and
n = 68 Czech), 83 patients with gestational diabetes mellitus (GDM), 34 type 1 diabetic patients screened negative
for glutamic acid decarboxylase (GAD), and 96 glucose tolerant individuals. The control group was randomly
selected from the population-based sampled Inter99 study.
Results: One novel heterozygous mutation c.17G>A, R6H, was identified in the pre-proinsulin gene (INS) in a
Danish MODYX family. The proband was diagnosed at 20 years of age with mild diabetes and treated with diet
and oral hypoglycaemic agent. Two other family members who carried the INS R6H were diagnosed with diabetes
when 51 years old and with GDM when 27 years old, respectively. A fourth mutation carrier had normal glucose
tolerance when 20 years old. Two carriers of INS R6H were also examined twice with an oral glucose tolerance test
(OGTT) with 5 years interval. They both had a ~30% reduction in beta-cell function measured as insulinogenic
index. In a Czech MODYX family a previously described R46Q mutation was found. The proband was diagnosed at
13 years of age and had been treated with insulin since onset of diabetes. Her mother and grandmother were
diagnosed at 14 and 35 years of age, respectively, and were treated with oral hypoglycaemic agents and/or insulin.
Conclusion: Mutations in INS can be a rare cause of MODY and we conclude that screening for mutations in INS
should be recommended in MODYX patients.
Background
Insulin gene (INS) mutations have recently been
described as a common cause of permanent neonatal
diabetes (PNDM) and a rare cause of diabetes diagnosed
in childhood or adulthood [1-4]. Heterozygous muta-
tions in INS account for 15 - 20% of cases of PNDM
[4,5]. Gene discovery can lead to recognition of novel
phenotypes [6] and recognition of novel clinical sub-
groups. For example, MODY was initially clinically
defined as autosomal dominantly inherited, non insulin
dependent, early-onset diabetes, but now there are at
least eight distinct genetic subgroups of MODY, most of
which have a discrete phenotype and specialized treat-
ment needs [6]. An R46Q INS mutation was recently
described in a Norwegian study of 62 probands fulfilling
conventional MODY criteria. In addition, they examined
223 patients from the population-based Norwegian
Childhood Diabetes Registry and found an R55C INS
mutation. One hundred blood donors were screened
negative for these mutations [7]. The Italian study group
on early onset diabetes has detected two INS mutations
(A23S and G23S) in children negative for 5 type 1 dia-
betes (T1D) autoantibodies [1]. In addition, an R6C
mutation was identified in an English MODY family and
a L68M mutation was described in a family of Turkish
origin with young-onset type 2 diabetes [3].* Correspondence: tweb@hagedorn.dk
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Furthermore, a recent screening for INS mutations in
252 patients diagnosed clinically with T1D between 6
months and 17 years of age identified 2 de novo hetero-
zygous mutations G32S and R89C among the 25 (8%)
antibody-negative patients [8]. To our knowledge, no
studies have screened women with gestational diabetes
mellitus (GDM) for INS mutation. GDM was defined as
an abnormal glucose tolerance diagnosed for the first
time in pregnancy.
We aimed to evaluate the prevalence and the disease-
associated phenotype of INS mutations among diabetic
patients diagnosed with MODY, anti-body negative T1D
or GDM.
Methods
INS was sequenced in 116 unrelated MODYX probands:
48 Danish, age at diagnosis (mean ± SD) 24 ± 19 years,
BMI 24.8 ± 5.5 kg/m2, and 68 Czech, age at diagnosis
18 ± 8 years, BMI 22.6 ± 5.0 kg/m2, 83 Danish diabetic
patients previously diagnosed with GDM, age at examina-
tion 40 ± 7 years, BMI at examination 28.1 ± 6.5 kg/m2,
34 GAD autoantibody-negative T1D patients, age at
diagnosis 20 ± 16 years and 96 glucose tolerant control
individuals, age at examination 46 ± 7 years, BMI 26.4 ±
4.4 kg/m2. All MODYX probands were from families
fulfilling the conventional criteria of MODY [5] defined
by: diabetes diagnosed before 25 years of age in at least
one of the family members. No treatment with insulin
and/or measurable C-peptide at least one year after
diagnosis. Autosomal dominant inherited diabetes with
known diabetes in at least two consecutive generations.
All MODY probands were screened negative for muta-
tions in the MODY genes HNF4A, GCK and HNF1A.
Women with GDM and all GAD autoantibody-negative
T1D patients had a positive family history of diabetes
including a diabetic parents and or child with diabetes.
The control group was randomly selected from the
population-based study Inter99 [9]. Additional family
members of the probands with an INS mutation were
examined and screened for the family-specific INS
mutation. The participants and examined family mem-
bers gave their informed written consent, and the study
protocols were approved by the ethical committees. The
genomic sequence of INS was analysed in two segments
covering the two exons, exon-intron boundaries and
UTRs. Sequencing analyses were performed as described
[4]. Analyses of the INS sequence revealed four low-
frequency (minor allele frequency = 0.05) and three
frequent (minor allele frequency>0.05) variants (Table 1).
Results and Discussion
One novel mutation c.17G>A, R6H, was identified in
INS in a Danish MODYX family (Figure 1A). The muta-
tion is located in the signal peptide of proinsulin and
was not present in 96 control individuals. The proband,
M132-1, had been diagnosed at 20 years of age with
mild diabetes treated with diet and oral hypoglycaemic
agent (OHA). His 20-years-old son, M132-2, carried the
mutation but had normal glucose tolerance. The brother
of the proband, M132-4, carried the mutation and
had been diagnosed with diabetes at 51 years of age.
A daughter, M132-5, of the brother carried the mutation
and had been diagnosed with IGT at the age of 26 and
with GDM at the age of 27 years. Two carriers of INS
R6H, M132-2 and M132-4, were also examined with an
OGTT at age 15 years and 46 years, respectively. Inter-
estingly, they both had a ~30% reduction in beta-cell
function over a period of 5 years measured as insulino-
genic index calculated from OGTT data (s-insulin 30
min (pmol/l) - s-insulin 0 min (pmol/l)/p-glucose 30
min (mmol/l). Insulinogenic index of M132-2 declined
from 50 to 33 and for M132-4 from 19 to 13. BMI for
M132-2 increased from 19.7 to 24.8 kg/m2; for M132-4
BMI was unchanged, 24.2 kg/m2, over the 5-year period.
Table 1 INS gene variants identified in MODY (n = 116), T1DM (n = 34), GDM (n = 83) and controls (n = 96)
MAF (%)
rs number SNP Position on chr. 11 Part of gene MODY
(n = 116)
T1D ab-
(n = 34)
GDM
(n = 83)
Controls
(n = 92)
Novel c.-218A>C 2.138.995 5’UTR 0.4 0 0 0
rs689 c.-23A>T 2.138.800 Intron 27 10 33 28
rs5505 c.-9C>T 2.138.786 5’UTR 0.9 0 0.6 0A
Novel c.17G>A, p.R6H 2.138.761 Exon 0.4 0 0 0
Novel c.137 G>A, p.R46Q 2.138.641 Exon 0.4 0 0 0
rs3842752 c.*9C>T 2.137.649 3’UTR 20 7 27 21
rs3842753 c.*22C>A 2.137.636 3’UTR 26 10 34 28
SNP locations (-strand) are displayed counting from the first translated nucleotide in pre-proinsulin (INS). Base-pair positions are displayed counting from the
p-arm telomere of chromosome 11 (according to the Base position feature in the Human (Homo sapiens) Genome Browser Gateway Human Mar. 2006 [hg18]
assembly (http://genome.ucsc.edu/cgi-bin/hgGateway, assessed 19 June 2009). Minor allele frequencies (MAF) are given as a percentage.
A) Subsequent genotyping of 198 population-based individuals revealed a MAF of 0.7%
Control individuals were collected as a subset of the population based study Inter99 of middle-aged Danish individuals.
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The R6 residue is conserved across mammalian species
(rhesus monkey, elephant, mouse, dog and horse) and
xenopus but is not conserved in lizard (S), platus (G) or
stikleback (Q). A mutation in the same codon, R6C, was
recently described in an English MODY family affecting
the proband, the mother and the maternal grandmother
[3], underlining a putative importance of this residue for
proper function of the signal peptide.
In a Czech MODY proband a previously described
R46Q mutation was found (Figure 1B). The mutation is
located at residue 22 of the B chain. The mutation co-
segregates with diabetes in two affected relatives and is
not present in any of the non-diabetic family members
or 96 controls. The proband, a 17-year old girl, was
diagnosed with diabetes at 13 years of age and had been
treated with insulin since onset of disease. Her mother
was diagnosed at 14 years of age with polyuria and poly-
dipsia, and had been treated with insulin since onset of
diabetes. The grandmother was diagnosed with diabetes
at 35 years of age and treated with OHA and insulin.
No coding mutations were found in GDM women or
GAD-negative type 1 diabetic patients.
It is very likely that the R46Q and R6H mutations are
disease causing and not just rare neutral polymorphisms.
In already published studies [1,3,7,8] a total of 1560
individuals primarily of Northern European ancestry
have been screened for INS mutations. The R46Q muta-
tion was identified in one Norwegian MODY family [7].
The mutation segregated with diabetes in the family.
The R6H mutation has not been identified in the 1560
examined individuals indicating that this mutation is not
a rare polymorphism. Furthermore, we have screened
additional 74 Danish individuals (data not shown) with-
out identifying the R46Q and R6H mutations.
Conclusion
Mutations in INS can be a rare cause of MODY and we
conclude that screening for mutations in INS should be
recommended in MODYX patients.
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